- Home
- BATL vs COEP Comparison
BATL vs COEP Comparison
Compare BATL & COEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BATL
- COEP
- Stock Information
- Founded
- BATL 1987
- COEP 2017
- Country
- BATL United States
- COEP United States
- Employees
- BATL N/A
- COEP N/A
- Industry
- BATL Oil & Gas Production
- COEP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BATL Energy
- COEP Health Care
- Exchange
- BATL Nasdaq
- COEP Nasdaq
- Market Cap
- BATL 29.9M
- COEP 32.4M
- IPO Year
- BATL N/A
- COEP N/A
- Fundamental
- Price
- BATL $1.62
- COEP $10.52
- Analyst Decision
- BATL
- COEP
- Analyst Count
- BATL 0
- COEP 0
- Target Price
- BATL N/A
- COEP N/A
- AVG Volume (30 Days)
- BATL 62.7K
- COEP 109.2K
- Earning Date
- BATL 03-28-2025
- COEP 03-25-2025
- Dividend Yield
- BATL N/A
- COEP N/A
- EPS Growth
- BATL N/A
- COEP N/A
- EPS
- BATL N/A
- COEP N/A
- Revenue
- BATL $191,482,000.00
- COEP N/A
- Revenue This Year
- BATL $2.21
- COEP N/A
- Revenue Next Year
- BATL N/A
- COEP N/A
- P/E Ratio
- BATL N/A
- COEP N/A
- Revenue Growth
- BATL N/A
- COEP N/A
- 52 Week Low
- BATL $1.31
- COEP $2.31
- 52 Week High
- BATL $7.08
- COEP $13.70
- Technical
- Relative Strength Index (RSI)
- BATL 39.04
- COEP 48.65
- Support Level
- BATL $1.63
- COEP $9.27
- Resistance Level
- BATL $1.77
- COEP $12.95
- Average True Range (ATR)
- BATL 0.14
- COEP 1.59
- MACD
- BATL 0.02
- COEP -0.33
- Stochastic Oscillator
- BATL 3.61
- COEP 38.56
About BATL Battalion Oil Corporation
Battalion Oil Corp is an independent oil and gas producer operating exclusively in the Delaware Basin. It is an independent energy company focused on the acquisition, production, exploration, and development of onshore liquids-rich oil and natural gas assets in the United States. The company operates in one segment which focuses on oil and natural gas acquisition, production, exploration, and development.
About COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.